European Joint Programme on Rare Diseases
The European Joint Programme on Rare Diseases brings over 130 institutions from 35 countries: 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Croatia, Ireland, Italy, Netherlands, Latvia, Lithuania, Malta, Poland,...
Coordinator: Daria Julkowska (Inserm, France)
Proyecto Genoma 1000 Navarra
NAGEN: Proyecto Genoma 1000 Navarra (NAGEN 1000) is an initiative led by the Navarrabiomed biomedical research centre whose purpose is to transfer the use of the cutting-edge whole human genome analysis technology to Navarra’s public health care system. To this end, 1,000 genomes of patients with...
Coordinator: Ángel Alonso (Navarrabiomed. Spain)
Training the next generation of researchers
ChromDesign is an innovative and interdisciplinary network of 10 European academic and private institutions. Our aim is to characterise how 3D chromatin organisation affects gene regulation during cellular differentiation and in several human disorders. ChromDesign’s main focus is to investigate...
Coordinator: Luciano Di Croce (CRG, Spain)
Solving the unsolved Rare Diseases
Patients with a rare disease generally go through a long and arduous process, sometimes lasting ten or fifteen years (also known as the rare disease odyssey), before finding a physician who knows what is wrong with them. Scientific advances can also take a long time, as it is difficult to find...
Coordinator: Olaf Riess, Holm Graessner (Tübingen, Germany)
SPIDIA for Personalized Medicine - Standardisation of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine
SPIDIA4P is a 48-month project funded by the European Commission under de H2020 program that brings together key experts of 19 stakeholder organisations, with the needed critical mass in knowledge on pre-analytical and analytical procedures, on European and international standardisation...
Coordinator: Uwe Oelmüller
Breast CAncer STratification - Understanding the determinants of risk and prognosis of molecular breast cancer subtypes. The aim of B-CAST is to identify women at moderate to high risk of breast cancer, the subtype of cancer that is most likely to develo
The B-CAST project (Breast CAncer STratification) is coordinated by the Netherlands Cancer Institute Antoni Van Leeuwenhoek and it will be conducted over five years (until September 2020). Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental...
Coordinator: Marjanka Schmidt

Pages